Moderna Prepares 2026-27 XFG COVID Booster as FDA Advisers Set to Vote
Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment
Neutral
Importance
7
Price
$47.13
Mkt Cap
$18.661B
52W Low
$22.28
52W High
$59.55
52W Position
112% above low
Off High
21% below high
Rel. Volume
0.5× avg
Market data snapshot near publication time
MRNA has more than doubled off its 52-week low of $22.28.
Summary
Moderna is preparing its 2026-27 COVID booster, specifically targeting the XFG strain. FDA advisers are scheduled to vote on updating the vaccine strain, which is a crucial regulatory step for the company's core vaccine franchise. The outcome of this advisory committee vote will be a significant indicator for the booster's path to market and potential future revenue.
At the time of this announcement, MRNA was trading at $47.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.7B. The 52-week trading range was $22.28 to $59.55. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.
Price Chart
MRNA - Latest Insights
MRNA
Oct 12, 2026, 9:04 AM EDT
Price at Filing:
$225.71
Real-time Price:
$213.88
Change:
-$11.83 (-5%)
Market Cap:
$85.389B
MRNA
Oct 01, 2026, 11:20 AM EDT
Price at Filing:
$198.05
Real-time Price:
$213.88
Change:
+$15.84 (+8%)
Market Cap:
$85.389B
MRNA
Sep 21, 2026, 1:34 PM EDT
Price at Filing:
$173.82
Real-time Price:
$213.88
Change:
+$40.07 (+23%)
Market Cap:
$85.389B
MRNA
Sep 01, 2026, 4:37 PM EDT
Price at Filing:
$152.00
Real-time Price:
$213.88
Change:
+$61.88 (+41%)
Market Cap:
$85.389B
MRNA
Sep 01, 2026, 2:28 AM EDT
Price at Filing:
$138.89
Real-time Price:
$213.88
Change:
+$74.99 (+54%)
Market Cap:
$85.389B